Aurora launches with $16 million to scale personalized CRISPR meds

US biotech start-up Aurora Therapeutics has launched with $16 million in seed funding from Menlo Ventures, aiming to turn one-off CRISPR gene-editing successes into a scalable model for rare diseases. The company argues that recent regulatory shifts and technical advances have finally lowered long-standing barriers.

Menlo Ventures incubated Aurora to tackle a core problem in rare disease genetics: most conditions involve hundreds or thousands of mutations, many too uncommon to justify conventional clinical development. Aurora says its platform can treat common and ultra-rare mutations in parallel under a unified strategy.

Edward Kaye has been appointed chief executive. Aurora was founded by Jennifer Doudna and Fyodor Urnov, building on work that includes the first bespoke CRISPR therapy used to treat an infant with CPS1 deficiency.